Related Experiment Video
Updated: Jan 12, 2026

Author Spotlight: An Effective Traditional Chinese Medicinal Treatment for Chronic Obstructive Pulmonary Disease with Abdominal Distension
Published on: September 1, 2023
Treatment Decisions for Stable Chronic Obstructive Pulmonary Disease in China: An Observational Cross-Sectional
Jiangyu Cui1, Chunli Tang1, Hongjia Li1
1Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, People's Republic of China.
Purpose:
To understand the current situation of respiratory and community physicians in China regarding the initial treatments for patients with chronic obstructive pulmonary disease (COPD).
Patients And Methods:
A multivariate discrete choice model was applied to simulate patients with stable COPD, and an online questionnaire was randomly provided to respiratory physicians and community physicians. The questionnaire responses and medications prescribed to the simulated patients by the doctors in the different groups were analyzed and compared.
Results:
(1) This study surveyed 109 doctors who made prescription decisions for 872 simulated COPD patients. (2) The results of the questionnaire revealed that the percentages of LAMA, LAMA/LABA and triple therapies that could be prescribed in community health care centers were 40.6%, 25%, and 34.4%, respectively. More than 60% of the physicians in the CHC and SH groups prescribed ICS/LABA as an initial regimen for maintenance therapy. (3) Triple therapy accounted for the highest proportion of prescriptions at 49%, followed by dual bronchodilator therapy (29.6%), whereas LAMA monotherapy represented the smallest share, with only 4.9% of prescriptions. Notably, ICS/LABA combination therapy represented a clinically relevant proportion of prescriptions (14.3%). A total of 58.9% of the 170 simulated COPD patients without asthma in the current study were prescribed triple therapy by their physicians. Approximately 60% of the COPD patients in Groups A and B were prescribed triple therapy as an initial treatment regimen, despite blood EOS counts of 100-300 cells/µL in both groups.
Conclusion:
Although most respiratory physicians follow guidelines for the choice of initial therapy for COPD, there are still irregularities in the use of triple therapy. A clinically relevant percentage of physicians, especially community physicians, selected ICS+LABA as the initial treatment choice. These practice irregularities should be the focus of future guidelines for promotion and education.
More Related Videos
07:10Home-Based Prescribed Pulmonary Exercise in Patients with Stable Chronic Obstructive Pulmonary Disease
Published on: August 24, 2019
04:24Acupoint Application as a Traditional Chinese Medicine Treatment for Fatigue Associated with Chronic Obstructive Pulmonary Disease
Published on: September 5, 2025
Related Concept Videos
Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation
Chronic Obstructive Pulmonary Disease-I: Introduction
Chronic Obstructive Pulmonary Disease
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
Medical History
COPD: Management Using Bronchodilators and Corticosteroids
Chronic Obstructive Pulmonary Disease-V: Nursing Management
Assessment